Epic Corp. (OTCPINK: EPOR) 52 week range: .03 to

New Post Public Reply Private Reply Replies (0) Message Board
FPPtrader

Epic Corp. (OTCPINK: EPOR)

52 week range: .03 to .55/share

Current share structure based on last annual report at Otcmarkets.com

Market Value1 $1.2M a/o Dec 10, 2012
Shares Outstanding 26M a/o Sep 30, 2012
Float 4.6M a/o Jul 18, 2012
Authorized Shares 150M a/o Dec 31, 2011

We estimate a public float of around 6.7M shares based on insider holdings in the last public filing

Business Description

EPIC is dedicated to making an impact on peoples lives. We strive to provide better health care through the development and commercialization of new technology. We realize, we cannot prosper in isolation. We and our strategic partners are using various technologies to develop economical devices to reduce trauma, aid in diagnosing diseases, and provide comfort. We are committed to grow our business by focusing on research and development, production, marketing, and sales of Health care products and services.

We achieve success through research and development conducted in conjunction with our affiliates and strategic partners. Our driving force is innovation in our products and financial matters, both measured in human and financial terms. In seeking the fulfillment of our mission, we are guided by values that establish who we are.

We were founded in October 1997, in the State of Colorado, and in September 1999 we became a full reporting company under the Securities Exchange Act of 1934 and started trading on the Bulletin Board. In December 2001 we voluntarily withdrew our registration under the Exchange Act, and have since traded on the OTC Markets. We survived the days of the "new economy" when our price was as high as $7.00 per share in March 2000 and descended to $0.01 more than a year later.

We commenced business as fab-less semi-conduct company, then evolved in to an information appliance company, a financial services holding company specializing in the development of subsidiary and affiliated companies. Then in 2006 we commenced focusing on the health care industry with the formation of RX Health care Systems, Ltd.

Our plan is to enter into agreements with companies developing technology for health care products. The essence of these agreements is to aid the companies with product commercialization, product procurement, marketing and distribution. Then once a product receives regulatory approval, if needed, and can be sold, we become the financial manager of a joint venture, directly or indirectly, with the research and development company.

The company for the next 12 months, will commence selling the AcuFAB and AcuPAD

Industry comparables:

Span-America Medical Systems Inc. (Nasdaq: SPAN)

52 week range: $13.35 to $19.93/share

Market cap: 54M

EBITDA: 8.71M

Invacare Corp (NYSE: IVC)

52 week range: $12.87 to $19.85/share

Market Cap: 462M

EBITDA: 131.22M

$18 billion per year in hospitalization cost

In 2011, a market study was performed to estimate the treatment costs and the costs of hospitals stays for patients who developed ulcers during hospitalization. These costs were estimated to be as much as $18 billion a year. In elderly populations and in those who are institutionalized, pressure ulcers are one of the most costly diseases to treat. These ulcers add an estimated burden of over $3 billion of expenditures and an additional 4.3 million Medicare hospital days to the United States health care system. The cost of treatment is $2000-$40,000 per pressure ulcer, depending on the stage of development.

For reconstructive surgery, costs are estimated at $25,000 per patient. These costs alone, without the cost of human suffering, demonstrate the importance of preventing pressure ulcers and of cost effective treatment practices. A 2011 cost-effective analysis study by Pham et al determined that both clinical and economic evidence maintains that pressure redistribution mattresses should be used to prevent pressure ulcers in long-term care patients. In addition, the study found that perineal foam cleansers and dry skin emollients are also economical ways to stop pressure ulcers from developing. Pham et al also concluded in a separate study that pressure redistribution foam mattresses should also be used to help improve elderly patients' health. http://emedicine.medscape.com/article/319284-overview

OxBridge Research
helping tomorrows fortune 500 companies TODAY!
Full Research Report: https://dl.dropbox.com/u/71480488/EPIC%20Mark...igence.pdf

Conclusion:

Epic Corporation has a proprietary and patent protected manufacturing process for a fabric solution which offers great advantages to the surface tissue in contact with it. In a world where we have major problems with sedentary lifestyles, poor eating habits, and health care issues, these solutions may be the answer for patients everywhere. What is most intriguing is that these products have some technological barriers to entry yet do not have to go through the rigorous FDA approval process. With some very reasonable hurdles, the company can get reimbursement for its products as the economic problem is very real and very large. This company is a very good way to play a global trend when the sentiment around such opportunities is at its lowest. The most compelling thing about this opportunity is its very low valuation, limited operational burn rate and its proprietary processes. Further, the mar ket overall is growing rapidly, and the overall demographic trend is fully intact. Finally, this company is a very good place to be if in fact the trend of pressure alleviation catches on in a very real way and transcends the existing products the company is currently involved with. There may be a large segment for custom business in several areas which have up until now not been looked at. This is a call option for the company as there are many areas such as gloves, footwear, hospital gowns, etc., where these products may very well be applicable and this is where It really gets interesting.

Happy Holiday's From The Team at FPP

As always bringing you the hottest uncompensated micro-cap stocks ahead of the crowd!

Recent Winners: ATRN 3600% , AUCI 200%, AXLX 300%, CMGO 900%, JNSH 250%, EGOC 300%, AMBS 750% VIP Twitter only Alert

Join our early alert / pre-promotion VIP membership for only $29.95/month for a limited time.

VIP's get exclusive access to our protected VIP twitter account and receive early alerts on our feature profiles as well as watch alerts on Nasdaq, NYSE, OTC, and Pinksheets stocks.

http://www.firstpennypicks.com/vip-membership/

Contact us: Info@FirstPennyPicks.com

FIRST PENNY PICKS DISCLAIMER

First Penny Picks Disclaimer is to be read and fully understood before using FirstPennyPicks.COM, or Joining our First Penny Picks Group or Newsletter.

Please note that FirstPennyPicks.COM employees are not registered as an Investment Adviser in any jurisdiction whatsoever.

We do not accept compensation for any of the companies profiled in our newsletter. We do however, from time to time buy shares in the companies profiled. If Firstpennypicks.com employees ,owners, or affiliates own shares in a profiled company the amount of shares will be listed at the bottom of each email. Firstpennypicks.com reserves the right to buy or sell shares in the profiled companies any time before during or after the advertisement is sent to our members. FPP's employees own a combined total of 180K shares of EPOR.

READ OUR FULL DISCLAIMER AT http://Firstpenny

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 446

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 56

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 250

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 333

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 38

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 90

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 104

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 612

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading

Top 5 Most Recently Viewed Articles

SOCi's AI Marketing: Leading G2's Summer 2026 Rankings

Updated Category News Views 12

AI's Rising Star in Enterprise Marketing Here's a tidbit worth chewing over your morning coffee: SOCi Inc., a name that's been buzzing in the enterprise circles, has nailed top spots in G2's Summer 2026 Report. We're talking about leading the charge in AI marketing and localized visibility, territories tough to crack unless you've got serious chops. In a world where...

Continue Reading
AI and the Future of Staffing: A Market Growth Story

Updated Category News Views 344

AI and the Future of Staffing: A Growth Story The staffing services market is on the verge of a major transformation, thanks in large part to advancements in Artificial Intelligence (AI). This evolution is projected to add an astounding USD 236.6 billion to the global staffing services market between 2024 and 2028. During this time, the market is expected to experience a...

Continue Reading
Optical Innovations Unite: OCC and Lightera's New Partnership

Updated Category News Views 317

Strategic Collaboration Between OCC and Lightera Optical Cable Corporation (NASDAQ: OCC) and Lightera, LLC are entering a significant partnership aimed at enhancing their product offerings primarily in the data center and enterprise sectors. This collaboration builds upon their long-term relationship, combining their strengths to create innovative optical connectivity...

Continue Reading
INFINOX Welcomes Artem Gonov as New Chief Technology Officer

Updated Category News Views 148

INFINOX Appoints Artem Gonov as Chief Technology Officer INFINOX, a globally recognized brokerage, has recently appointed Artem Gonov as its new Chief Technology Officer (CTO). This strategic move underlines the company's commitment to enhancing its technology landscape and providing exceptional platforms for its clients. Artem Gonov's Background and Expertise Mr. Gonov...

Continue Reading
George Medicines’ GMRx2 Sets New Standard for Hypertension Care

Updated Category News Views 126

George Medicines Introduces GMRx2 for Hypertension Management Recent findings published in The Lancet highlighted the promising results of a Phase III trial for GMRx2, a novel triple combination pill aimed at managing hypertension. Developed by George Medicines, this medication is making waves in the field of cardiovascular care as it demonstrates significant advancements...

Continue Reading